# Astraea

> Astraea is a San Francisco startup building an AI-native operating system for clinical trial biometrics. Its agentic platform turns raw study data and a protocol into FDA-ready outputs - SDTM and ADaM datasets, TFLs, and submission packages - compressing work that normally takes months into days while keeping humans in the loop for review and regulatory sign-off. Founded in 2026 by Stanford's Joshua Wang and Sanmay Sarada, the company is part of Y Combinator's Spring 2026 (P26) batch.

- **Founded:** 2026
- **Headquarters:** San Francisco, California, United States
- **Founders:** Joshua Wang (Co-Founder & CEO), Sanmay Sarada (Co-Founder & CTO)
- **Team size:** 2-4
- **Products:** Astraea Clinical Biometrics Platform, Standards, Compliance, Evidence & Stats Engines
- **Notable:** Accepted into Y Combinator's Spring 2026 (P26) batch, Built an end-to-end agentic pipeline from raw clinical data to FDA-ready outputs, Founding team combines competition-level math/CS (USAMO top 250, USACO Platinum) with published fetal-medicine data research

## Products & services

- **Astraea Clinical Biometrics Platform** — An AI-native operating system that ingests raw clinical data, a protocol, and study metadata, then automates SAP, eCRF and TFL shell generation, CDISC-compliant SDTM and ADaM datasets, tables/figures/listings, traceable statistical programs, and QC to produce FDA-ready outputs. Deployed within the sponsor's own environment for data privacy.
- **Standards, Compliance, Evidence & Stats Engines** — Four specialized AI engines that handle CDISC-native mapping with Pinnacle 21 validation, 21 CFR Part 11 compliance, evidence traceability, and statistical analysis across the clinical development lifecycle.

## Achievements

- Accepted into Y Combinator's Spring 2026 (P26) batch
- Built an end-to-end agentic pipeline from raw clinical data to FDA-ready outputs
- Founding team combines competition-level math/CS (USAMO top 250, USACO Platinum) with published fetal-medicine data research

## Latest updates

- **2026-05** — Launched publicly via Y Combinator as 'Agents Accelerating clinical trials.'
- **2026-03** — Raised a $130K seed round associated with the Y Combinator Spring 2026 batch.

## Links

- Website: https://tryastraea.com
- LinkedIn: http://www.linkedin.com/company/astraeabio
- Twitter/X: https://x.com/joshwqngsr

---

Profile page: https://yespress.io/astraea-yc-p26
Published by YesPress — https://yespress.io
Last updated: 2026-07-31